Oncolys BioPharma (TSE:4588) Debt-to-EBITDA : N/A (As of Jun. 2026)

Oncolys BioPharma  (TSE:4588) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

Oncolys BioPharma Debt-to-EBITDA Related Terms

The historical data trend for Oncolys BioPharma's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Oncolys BioPharma Debt-to-EBITDA Chart

Oncolys BioPharma Annual Data
	Trend	Dec16	Dec17	Dec18	Dec19	Dec20	Dec21	Dec22	Dec23	Dec24	Dec25
Debt-to-EBITDA		Get a 7-Day Free Trial					-0.31	-0.35	-0.16	-0.19	-0.16

Oncolys BioPharma Quarterly Data
	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Dec24	Mar25	Jun25	Dec25	Mar26	Jun26
Debt-to-EBITDA	Get a 7-Day Free Trial															-0.09	-0.18	N/A	-0.44	N/A

TSE:4588 vs VRTX, REGN, MRNA: Debt-to-EBITDA Comparison

For the Biotechnology subindustry, Oncolys BioPharma's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Oncolys BioPharma Debt-to-EBITDA vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oncolys BioPharma's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Oncolys BioPharma's Debt-to-EBITDA falls into.

Oncolys BioPharma Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Oncolys BioPharma's Debt-to-EBITDA for the fiscal year that ended in Dec. 2025 is calculated as

Oncolys BioPharma's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2026 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Jun. 2026) EBITDA data.

Oncolys BioPharma Business Description